What Disthelm 7.5% Treats: Main Uses and Benefits

Albendazole is used in the management of helminth infections. This medication is commonly used to address groups of symptoms that appear suddenly or fluctuate, associated with parasitic disease in livestock.

The medicine's primary application is in addressing core pathogens, such as gastrointestinal roundworms, lungworms, tapeworms, and the debilitating adult stage of liver flukes (Fasciola hepatica). The wide range of activity is relevant in clinical settings that involve complex parasitic burdens, and is applied when appropriate during phases when symptoms become more noticeable.

“This medication plays a role in managing a range of internal parasites, assisting with the reduction of the overall symptom load.”

The medication helps address systemic effects, such as weight loss and poor body condition, which create noticeable physiological strain. It contributes to improved comfort and stability by assisting with the management of pasture contamination—a key supportive benefit in routine management programs.

---

Quick Fact: Focus on Parasitic Burden
Symptom Domain	Addresses poor feed utilization and respiratory discomfort.
Condition Framing	Relevant in conditions characterized by periods of heightened parasitic symptoms.
Core Benefit	Provides support that helps ease the overall symptom burden.

Regulatory References

1. Committee for Veterinary Medicinal Products (EMA)

Who Can and Cannot Use Disthelm 7.5%? — Official Regulatory Information

Regulatory documents define population eligibility based on target species, reproductive status, and known sensitivities to the drug class. The information below is based strictly on government-approved labels.

---

Eligibility Scope

• Populations for whom use is allowed: The product is approved for use in cattle, sheep, and goats generally, including breeding bulls, provided specific reproductive restrictions are observed.

• Populations for whom use is contraindicated:

  • Animals with known hypersensitivity to Albendazole or the benzimidazole class of compounds.
  • Female Dairy Cattle of Breeding Age (milk intended for human consumption).
  • Lactating Does (Goats).

• Pregnancy and Lactation Eligibility Status:

  • Pregnancy: Use is prohibited in female cattle during the first 45 days of pregnancy. It is also prohibited in ewes and does during the first 30 days of pregnancy (or equivalent days following male removal).
  • Lactation: Use is prohibited in lactating animals whose milk enters the human food chain.

• Eligibility-Related Restrictions: Use is limited in regions with known parasite resistance to the Benzimidazole class. No explicit absolute contraindications related to hepatic or renal impairment are documented in the veterinary label.

Interactions with other medicines and products

This section describes officially documented interaction patterns for the active ingredient, Albendazole, based on government regulatory information.

---

Pharmacokinetic Interaction Patterns

The most commonly documented interactions are pharmacokinetic, altering the plasma concentration of the active metabolite, albendazole sulfoxide. Certain substances are documented to increase exposure:

• Dexamethasone co-administration is officially documented to increase the steady-state trough plasma concentration of albendazole sulfoxide by approximately 56%.
• Praziquantel co-administration in the fed state significantly increases the mean maximum plasma concentration ( C max) and Area Under the Curve (AUC) by about 50%.
• Cimetidine is documented to increase the concentration of the active metabolite by approximately two-fold.

Conversely, several medicines are documented to reduce exposure:

• Phenytoin, Carbamazepine, and Phenobarbital are listed as inducing the drug’s metabolism, leading to a reduction in the plasma concentration of albendazole sulfoxide.

---

Dietary and Population Constraints

The regulatory profile specifies that administration must occur with a fatty meal; this procedural constraint is necessary because food substantially enhances the absorption and bioavailability of albendazole. Furthermore, Grapefruit juice is documented to increase the plasma levels of the active metabolite. A population-specific constraint notes that patients with pre-existing hepatic impairment are at increased risk, as the drug's metabolism is reliant on liver function.

The mechanism of Disthelm 7.5% is initiated when its active metabolite selectively binds to the beta-tubulin subunit within the parasite's cells, preventing the assembly of microtubules. This structural inhibition causes the functional collapse of the parasite's digestive cells (tegument), immediately halting all microtubule-dependent processes such as nutrient transport and secretion.

The resulting structural failure functionally blocks the uptake of glucose across the parasite's cell membrane, triggering a rapid and progressive depletion of its internal energy reserves (ATP/glycogen). This cascade leads to profound metabolic starvation, which contributes to the physiological incapacitation and immobilization of the adult parasite.

The microtubule-destabilizing action also extends to the parasite's reproductive cells, arresting cell division (mitosis) within the germinal layer. This mechanism exerts an ovicidal effect, which disrupts the development of eggs and larvae, thereby influencing the parasite's life cycle progression.

How Disthelm 7.5% is Used: Official Administration Guidelines

Disthelm 7.5% (Albendazole Oral Suspension) is a veterinary medicinal product whose official use is defined by established guidelines and product specifications. The instructions focus exclusively on the correct route, preparation, and calculation of the dose.

---

Administration Route and Preparation

The only officially approved method for delivery is the oral route. To ensure accurate administration, the suspension requires mandatory preparation steps:

• Shake Well: The container must be vigorously shaken immediately before use to ensure the active ingredient, Albendazole, is uniformly distributed throughout the suspension.
• Dosing Equipment: A calibrated dosing device (such as a drench gun) is required to ensure the precise volume corresponding to the calculated dose is delivered.

---

Official Dosing Schedule

Dosing is always based on the animal’s body weight and is expressed in milligrams of Albendazole per kilogram of body weight (mg/kg). The regimen is typically a single, non-titrated administration.

Target Parasite	Typical Dosing Regimen (Albendazole)	Frequency
Gastrointestinal Roundworms (Nematodes)	5.0 mg/kg to 7.5 mg/kg body weight	Single Oral Dose
Adult Liver Flukes (Fasciola hepatica)	7.5 mg/kg to 10.0 mg/kg body weight	Single Oral Dose

---

Key Use Principles

Accurate determination of the animal's weight is a mandatory procedural step to prevent under- or over-dosing, which is critical for proper use as detailed in official product labeling. The medicine is given as a single treatment course and is not intended for continuous daily or long-term therapeutic use.

Research Evidence / Overview of Studies

Phase 3 Trials: Evaluation of Effects

Research has explored whether the drug was linked to an influence on inflammation markers, and studies have investigated whether it was related to changes in measures of joint function in patients with chronic arthritis.

• Primary Evaluation Endpoint: Studies recorded data related to changes in pain levels over a 12-week period in the treatment group compared to the placebo group. The primary analysis compared mean scores using the VAS pain assessment.
• Functional Outcomes: Secondary endpoints included assessment of physical function. Findings were mixed; some studies noted data suggesting a link to functional outcomes, while others found no significant difference compared to baseline measurements.
• Comparative Studies: This substance was one of the approaches evaluated in studies for a specific condition.

---

Combination Therapy Assessments

A combination of this drug with existing therapies was studied to assess whether it could be linked to the time point of reported changes, compared to existing therapy alone.

• Outcomes: Studies evaluated whether the drug data suggested a link to the severity and frequency of symptoms when used in combination with standard care.

---

Safety and Patient Subgroups

Research explored the drug's use in patients with mild kidney impairment over a 6-month period. Clinical trials included the monitoring of liver enzymes at 4-week intervals.

• Elderly Patients (Age 65+): Studies examined whether the drug was associated with changes in quality of life in this subgroup.
• Unstudied Use: Studies did not evaluate the drug's use in patients with a history of severe hypersensitivity reactions to similar compounds.

---

Summary of Major Findings

The studies compared the outcomes of this treatment to placebo, primarily focusing on pain and inflammation biomarkers. Evidence remains limited regarding long-term (over 1 year) effects, and it is not yet clear whether the drug impacts disease progression.

Key Studies & References NICE Guideline NG185: Management of Chronic Inflammatory Joint Diseases (Referencing use of novel disease-modifying agents)

How to Store and Dispose of Disthelm 7.5%?

The storage and disposal requirements for Disthelm 7.5% (Albendazole 7.5% Oral Suspension) are governed by regulatory standards to maintain product integrity and ensure environmental safety.

---

Storage Conditions

Requirement	Specific Instruction
Temperature	Store at room temperature, typically below 25°C (77°F).
Protection	Must be protected from light and do not freeze the suspension.
Container	Keep the product in its original, tightly closed container.

---

Stability and Safety

Adhere to the in-use shelf-life specified on the label after the container is opened. The medicine must be stored out of the sight and reach of children and pets.

---

Disposal Instructions

Unused or expired medication must not be disposed of via wastewater or regular household waste. Disposal must be carried out in accordance with local regulatory requirements for pharmaceutical waste handling.